Page last updated: 2024-11-13

ro5166017

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RO5166017: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25016538
CHEMBL ID3779993
SCHEMBL ID503167
MeSH IDM0587786

Synonyms (28)

Synonym
ro5166017
(4s)-4-[(n-ethylanilino)methyl]-4,5-dihydro-1,3-oxazol-2-amine
ro 5166017
ro-5166017
gtpl5862
(s)-4-[(ethyl-phenyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine
PPONHQQJLWPUPH-JTQLQIEISA-N ,
SCHEMBL503167
CHEMBL3779993 ,
1048346-74-2
AKOS027253395
(s)-4-((ethyl(phenyl)amino)methyl)-4,5-dihydrooxazol-2-amine
mfcd22493512
bdbm50158431
AS-43509
Q7277303
YK98JFQ52U ,
(4s)-2-amino-n-ethyl-4,5-dihydro-n-phenyl-4-oxazolemethanamine
4-oxazolemethanamine, 2-amino-n-ethyl-4,5-dihydro-n-phenyl-, (4s)-
(s)-4-((ethyl-phenyl-amino)-methyl)-4,5-dihydro-oxazol-2-ylamine
(4s)-4-((n-ethylanilino)methyl)-4,5-dihydro-1,3-oxazol-2-amine
A906895
unii-yk98jfq52u
n-ethyl-n-{[(4s)-2-imino-1,3-oxazolidin-4-yl]methyl}aniline
DTXSID801030323
CS-0012278
(4s)-4-{[ethyl(phenyl)amino]methyl}-4,5-dihydro-1,3-oxazol-2-amine
HY-12699

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with RO5166017 before extinction hindered the formation of extinction long-term memory."( Effects of Trace Amine-associated Receptor 1 Agonists on the Expression, Reconsolidation, and Extinction of Cocaine Reward Memory.
Li, JX; Liu, JF; Thorn, DA; Zhang, Y, 2016
)
0.76
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Trace amine-associated receptor 1Mus musculus (house mouse)EC50 (µMol)0.00300.00200.69705.4000AID1288307
Trace amine-associated receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)0.01400.01390.42632.0440AID1288305
Trace amine-associated receptor 1Homo sapiens (human)EC50 (µMol)0.05900.01501.41437.1900AID1288302
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityTrace amine-associated receptor 1Homo sapiens (human)
trace-amine receptor activityTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1346375Human TA1 receptor (Trace amine receptor)2011Proceedings of the National Academy of Sciences of the United States of America, May-17, Volume: 108, Issue:20
TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity.
AID1346358Rat TA1 receptor (Trace amine receptor)2011Proceedings of the National Academy of Sciences of the United States of America, May-17, Volume: 108, Issue:20
TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity.
AID1346295Mouse TA1 receptor (Trace amine receptor)2011Proceedings of the National Academy of Sciences of the United States of America, May-17, Volume: 108, Issue:20
TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity.
AID1288304Selectivity ratio of EC50 for human adrenergic alpha 2A receptor expressed in CHL cells to EC50 for human TAAR1 expressed in recombinant HEK293 cells2016ACS medicinal chemistry letters, Feb-11, Volume: 7, Issue:2
Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.
AID1288303Agonist activity at human TAAR1 expressed in recombinant HEK293 cells assessed as cAMP accumulation after 30 mins by luminometer relative to phenethylamine2016ACS medicinal chemistry letters, Feb-11, Volume: 7, Issue:2
Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.
AID1288307Agonist activity at mouse TAAR1 expressed in recombinant HEK293 cells assessed as cAMP accumulation after 30 mins by luminometer2016ACS medicinal chemistry letters, Feb-11, Volume: 7, Issue:2
Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.
AID1288305Agonist activity at rat TAAR1 expressed in recombinant HEK293 cells assessed as cAMP accumulation after 30 mins by luminometer2016ACS medicinal chemistry letters, Feb-11, Volume: 7, Issue:2
Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.
AID1288302Agonist activity at human TAAR1 expressed in recombinant HEK293 cells assessed as cAMP accumulation after 30 mins by luminometer2016ACS medicinal chemistry letters, Feb-11, Volume: 7, Issue:2
Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's11 (91.67)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.60 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]